RxDoctor Payments DataLook up a doctor →

Gaurav Gupta, MD

Nephrology · Richmond, VANPI 1083808695

Payments from drug & device makers

$2,099,693in general payments, 2019–2025

Across 514 payments — averaging $4085.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.5M
  • CSL Behring$245K
  • AstraZeneca$127K
  • Novartis$114K
  • Mallinckrodt Hospital Products Inc.$33K
  • Mallinckrodt Enterprises LLC$27K
  • plus $43K from 15 others

What the payments were for

  • Consulting fees$33,27620%
  • Speaking & faculty fees$112,38067%
  • Travel & lodging$17,98811%
  • Food & beverage$4,3293%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,099,693 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$75,628
Medicare patients
246
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab26$738,154
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$402,951
JardianceEmpagliflozin111$69,345
OzempicSemaglutide33$29,668
EliquisApixaban26$19,607
Envarsus XrTacrolimus12$12,581
Atovaquone15$10,290
FarxigaDapagliflozin Propanediol15$9,630
Valganciclovir Hcl38$6,802
Mycophenolic AcidMycophenolate Sodium12$4,515
Cinacalcet Hcl68$2,924
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$2,517
Nifedipine ErNifedipine95$2,485
Methenamine Hippurate24$1,476
Carvedilol238$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris, Farxiga$126,691$747,78441 claims
Boehringer IngelheimJardiance$14$69,345111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 298 nephrology providers in Virginia.

Other nephrology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →